Please login to the form below

Not currently logged in
Email:
Password:

Hospira CEO joins board of Kythera

Michael Ball named director of aesthetic medicine specialist

Kythera Michael BallKythera Biopharmacueticals has appointed Hospira's CEO Michael Ball to the company's board of directors.

Ball has served as CEO at Hospira, creators of the first biosimilar to be launched in the EU, since 2011.

He joined the company following a 16-year stint at Botox developers Allergan, serving as president from 2006. His earlier roles at Allergan included president of pharmaceuticals and president for North America.

This experience in aesthetic products such as Botox will serve him well in his role at Kythera, with the company currently developing ATX-101 as an injectable treatment for the reduction of fat under the chin and around the neck. The drug is currently in phase III development.

"We are thrilled to have him on board,” commented Keith Leonard, Kythera's president and CEO. “His knowledge and perspective will support our mission to bring innovation to the growing area of aesthetic medicine."

2nd October 2013

From: Research, Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Grace Communications

Grace Communications is a creative agency specialising in healthcare communication and understanding people's personality types....

Latest intelligence

It’s all about patient outcomes… right?
Lessons from history: a design thinking perspective...
Emma Walmsley 2
30 Women Leaders in UK Healthcare (part 3)
Continuing our special feature on Women Leaders in UK Healthcare...
Louise Houson
30 Women Leaders in UK Healthcare
The enormous challenges facing UK healthcare mean it needs great leaders. PME’s Group Editor Andrew McConaghie introduces 30 outstanding innovators and trailblazers helping to shape the future...

Infographics